| _version_ |
1860797433723748352
|
| building |
INTELEK Repository
|
| collection |
Online Access
|
| collectionurl |
https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
|
| date |
2024-08-27 13:02:23
|
| format |
Restricted Document
|
| id |
12698
|
| institution |
UniSZA
|
| internalnotes |
1. Wortmann RL. Gout and hyperuricemia. Current Opinion Rheumatology 2002;14:281-6. 2. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005; 143:499-516. 3. Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatology 2002; 29:2403- 6. 4. Klemp P, Stansfield SA, Castle B & Robertson MC (1997). Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56:22-6. 5. Dalbeth N, Collis J, Gregory K, et al. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 2007; 46:1804- 7. 6. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatology 2004; 31:1582-7. 7. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-1996). J Rheumatology 2001; 28:1640-6. 8. Mohd A, Das Gupta E, Loh YL, et al. Clinical characteristics of gout: A hospital case series. Malaysian Family Physician 2011; 6:2-3. 9. Wallace C, Newhouse SJ, Braund P, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008; 82:139-49. 10. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 39 Volume 14 Number 2, Dec 2015 2007; 3:e194. 11. Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008; 372:1953-61. 12. Urano W, Taniguchi A, Anzai N, et al. Association between GLUT9 and gout in Japanese men. Ann Rheum 2010, 69:932-3. 13. Hollis-Moffatt JE, Gow PJ, Harrison AA, et al. The SLC2A9 nonsynonymopus Arg256His variant and gout: evidence for a population-specific effect on severity. Arthritis Research & Therapy 2011, 13:R85. 14. Tu HP, Chen CJ, Tovosia S, et al. Associations of nonsynonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese subjects and Solomon Islanders. Ann Rheum 2009; 69:887- 90. 15. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40:437- 42. 16. Doring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008; 40:430-6. 17. McArdle PF, Parsa A, Chang YP, et al. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in Old Order Amish. Arthritis Rheum 2008; 58:2874-81. 18. Brandstatter A, Kiechl S, Kollerits B, et al. Sex- specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care 2008; 31:1662-7. 19. Zemunik T, Bohan M, Lauc G, et al. Genome- wide association study of biochemical traits in Korcula Island, Croatia. Croat Med J 2009; 50:23-33. 20. Stark K, Reinhard W, Neureuther K,et al. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS One 2008; 9:e1948. 21. Hollis-Moffatt JE, Xu X, Dalbeth N, et al. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island and Caucasian case-contril sample sets. Arthritis & Rheumatology 2009; 60:3485- 92. 22. Phipps-Green AJ, Merriman ME, Topless R, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Clinical and Epidemiological Research 2014; 1:1-7. 23. Saag KG, Choi HK. Epidemiology, risk factors, and lifestyle modifications in gout. Arthritis Res Ther 2006; 8:S2. 24. Yahyaoui R, Esteva I, Haro-Mora JJ, et al. Effect of long term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol
|
| originalfilename |
7006-01-FH02-FSK-16-04818.pdf
|
| person |
Adobe Acrobat Pro DC 20.6.20042
|
| recordtype |
oai_dc
|
| resourceurl |
https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12698
|
| spelling |
12698 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12698 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal application/pdf 7 Adobe Acrobat Pro DC 20 Paper Capture Plug-in with ClearScan 1.6 Adobe Acrobat Pro DC 20.6.20042 2024-08-27 13:02:23 7006-01-FH02-FSK-16-04818.pdf UniSZA Private Access Suggestive Evidence of Slc2a9 Polymorphisms Association in Gouty Malay Males International Medical Journal of Malaysia Introduction: Solute carrier family 2, member 9 (SLC2A9) is thought to be an important urate transporter that influences the excretion and reabsorption of serum uric acid, thus has a strong effect on serum urate and risk of gout. SLC2A9 polymorphisms have been extensively studied in various populations in association with gout development. Our aim was to test for association of SLC2A9 SNPs with gout in Malay males. Methods: 78 gouty patients and 82 normal subjects were recruited and genotyped for rs3733591, rs5028843 and rs11942223 using PCR-RFLP technique. Single association and haplotype association analyses were conducted using SHEsis online software. Results: rs3733591 and rs5028843 showed association with gout with p value of 0.020 and 0.036, respectively, whilst rs11942223 yielded no association with p value of 0.08 with trend towards susceptibility projecting by OR=3.547, 3.667 and 2.732, respectively. It is noteworthy that haplotype 1/1/1 conferred protection in gout with p value 0.004 (OR=0.324 [0.147-0.716]). Conclusion: This study might suggest an evidence of association of SLC2A9 SNPs with gout among Malay males. 14 2 International Islamic University Malaysia International Islamic University Malaysia 35-39 1. Wortmann RL. Gout and hyperuricemia. Current Opinion Rheumatology 2002;14:281-6. 2. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005; 143:499-516. 3. Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatology 2002; 29:2403- 6. 4. Klemp P, Stansfield SA, Castle B & Robertson MC (1997). Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56:22-6. 5. Dalbeth N, Collis J, Gregory K, et al. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 2007; 46:1804- 7. 6. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatology 2004; 31:1582-7. 7. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-1996). J Rheumatology 2001; 28:1640-6. 8. Mohd A, Das Gupta E, Loh YL, et al. Clinical characteristics of gout: A hospital case series. Malaysian Family Physician 2011; 6:2-3. 9. Wallace C, Newhouse SJ, Braund P, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008; 82:139-49. 10. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 39 Volume 14 Number 2, Dec 2015 2007; 3:e194. 11. Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008; 372:1953-61. 12. Urano W, Taniguchi A, Anzai N, et al. Association between GLUT9 and gout in Japanese men. Ann Rheum 2010, 69:932-3. 13. Hollis-Moffatt JE, Gow PJ, Harrison AA, et al. The SLC2A9 nonsynonymopus Arg256His variant and gout: evidence for a population-specific effect on severity. Arthritis Research & Therapy 2011, 13:R85. 14. Tu HP, Chen CJ, Tovosia S, et al. Associations of nonsynonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese subjects and Solomon Islanders. Ann Rheum 2009; 69:887- 90. 15. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40:437- 42. 16. Doring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008; 40:430-6. 17. McArdle PF, Parsa A, Chang YP, et al. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in Old Order Amish. Arthritis Rheum 2008; 58:2874-81. 18. Brandstatter A, Kiechl S, Kollerits B, et al. Sex- specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care 2008; 31:1662-7. 19. Zemunik T, Bohan M, Lauc G, et al. Genome- wide association study of biochemical traits in Korcula Island, Croatia. Croat Med J 2009; 50:23-33. 20. Stark K, Reinhard W, Neureuther K,et al. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS One 2008; 9:e1948. 21. Hollis-Moffatt JE, Xu X, Dalbeth N, et al. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island and Caucasian case-contril sample sets. Arthritis & Rheumatology 2009; 60:3485- 92. 22. Phipps-Green AJ, Merriman ME, Topless R, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Clinical and Epidemiological Research 2014; 1:1-7. 23. Saag KG, Choi HK. Epidemiology, risk factors, and lifestyle modifications in gout. Arthritis Res Ther 2006; 8:S2. 24. Yahyaoui R, Esteva I, Haro-Mora JJ, et al. Effect of long term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol
|
| spellingShingle |
Suggestive Evidence of Slc2a9 Polymorphisms Association in Gouty Malay Males
|
| summary |
Introduction: Solute carrier family 2, member 9 (SLC2A9) is thought to be an important urate transporter that influences the excretion and reabsorption of serum uric acid, thus has a strong effect on serum urate and risk of gout. SLC2A9 polymorphisms have been extensively studied in various populations in association with gout development. Our aim was to test for association of SLC2A9 SNPs with gout in Malay males. Methods: 78 gouty patients and 82 normal subjects were recruited and genotyped for rs3733591, rs5028843 and rs11942223 using PCR-RFLP technique. Single association and haplotype association analyses were conducted using SHEsis online software. Results: rs3733591 and rs5028843 showed association with gout with p value of 0.020 and 0.036, respectively, whilst rs11942223 yielded no association with p value of 0.08 with trend towards susceptibility projecting by OR=3.547, 3.667 and 2.732, respectively. It is noteworthy that haplotype 1/1/1 conferred protection in gout with p value 0.004 (OR=0.324 [0.147-0.716]). Conclusion: This study might suggest an evidence of association of SLC2A9 SNPs with gout among Malay males.
|
| title |
Suggestive Evidence of Slc2a9 Polymorphisms Association in Gouty Malay Males
|
| title_full |
Suggestive Evidence of Slc2a9 Polymorphisms Association in Gouty Malay Males
|
| title_fullStr |
Suggestive Evidence of Slc2a9 Polymorphisms Association in Gouty Malay Males
|
| title_full_unstemmed |
Suggestive Evidence of Slc2a9 Polymorphisms Association in Gouty Malay Males
|
| title_short |
Suggestive Evidence of Slc2a9 Polymorphisms Association in Gouty Malay Males
|
| title_sort |
suggestive evidence of slc2a9 polymorphisms association in gouty malay males
|